Merck & Co. & European Union

Merck & Co.: Merck & Co. is collaborating with The Hashgraph Association to integrate its M-Trust physical authentication technology, aiming to meet EU product transparency regulations and enhance its supply chain solutions.

European Union: The European Union's incoming product transparency regulations, such as the Ecodesign for Sustainable Products Regulation (ESPR) and EU Deforestation Regulation (EUDR), are the primary drivers for this collaboration, creating a demand for the integrated solution.

Merck & Co.: Merck & Co. benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Pembrolizumab therapy, potentially increasing the drug's market reach.

European Union: The European Union's In Vitro Diagnostic Regulation (IVDR) provided the regulatory framework for the approval of the VENTANA MMR RxDx Panel, enabling its availability in member countries.

Merck & Co.: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

European Union: The European Union considers the risk to its general public very low but has begun coordinating laboratory preparedness and traveler guidance through its Health Security Committee.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.

European Union: A spokesperson for the European Union>>> stated that the risk of an Ebola outbreak in Europe is 'very low', indicating monitoring of the situation but no immediate alarm for the region.